Trials / Completed
CompletedNCT02173899
Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 716 (actual)
- Sponsor
- Changchun Keygen Biological Products Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 1 Year – 7 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | varicella-1 | Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day |
| BIOLOGICAL | varicella-3 | Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day |
| BIOLOGICAL | varicella-5 | Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2014-06-25
- Last updated
- 2014-09-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02173899. Inclusion in this directory is not an endorsement.